Oscar Health CFO Richard Blackley sells $2.75m in common stock
Oscar Health CFO Richard Blackley sold 110,000 shares of Class A common stock for $2.75 million on May 18, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while Oscar Health shares are near their 52-week high, following an 88% surge in six months. Analysts predict the company will turn profitable this year with projected earnings of $1.20 per share, a significant improvement from a recent loss.
CFO’s 110,000-share Oscar Health (NYSE: OSCR) sale is pre-planned
Oscar Health's CFO, Richard Scott Blackley, sold 110,000 shares of Class A Common Stock for $25.03 per share, totaling $2.75 million. This transaction was pre-arranged under a Rule 10b5-1 trading plan adopted on February 12, 2026. Following the sale, Blackley directly holds 1,106,660 shares, with an additional 75,000 shares held indirectly by the MQB Irrevocable Trust.
Oscar Health (NYSE: OSCR) CFO sells 100,000 shares in planned trade
Oscar Health's CFO, Richard Scott Blackley, sold 100,000 shares of Class A Common Stock on May 14, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. The sales occurred in two tranches with weighted average prices of $23.79 and $23.10, totaling over $2.3 million. Despite the sale, Blackley retains significant holdings, including 75,000 shares held indirectly through a trust.
Oscar Health, Inc. Class A Trade Ideas — BIVA:OSCR
This article compiles several trade ideas and analyses for Oscar Health, Inc. (OSCR) from various traders on TradingView. The collective sentiment is largely bullish, highlighting impressive growth, potential breakouts, and undervalued status, despite acknowledged risks like razor-thin margins and political ties to ACA subsidies. Traders discuss technical indicators, price targets, and entry/exit strategies, with some even comparing the stock's chart patterns to Bitcoin.
Oscar Health, Inc. Class A Trade Ideas — BOATS:OSCR
This article compiles several trade ideas and analyses for Oscar Health, Inc. (OSCR) from various traders on TradingView. The common themes include the company's impressive revenue growth, increasing market share, and potential for significant stock price appreciation, often highlighted by technical analysis such as breakout patterns and cup-and-handle formations. While some analysts acknowledge risks like political factors and current low margins, many see OSCR as undervalued with strong long-term potential due to its disruptive approach to health insurance and recent positive earnings reports.
Oscar Health, Inc. Class A Trade Ideas — SWB:9VY
This article compiles various trade ideas and analyses for Oscar Health, Inc. Class A (SWB:9VY, NYSE:OSCR) from multiple traders on TradingView. The ideas range from bullish outlooks based on technical patterns, company expansion plans, and strong financial performance, to short-term bearish predictions based on resistance levels. Many analysts highlight Oscar Health's innovative approach in the health insurance industry and its potential for significant upside.
[10-Q] Oscar Health, Inc. Quarterly Earnings Report
Oscar Health, Inc. reported significantly improved financial results for the quarter ended March 31, 2026, with total revenue increasing to $4.65 billion and net income attributable to the company rising to $679.0 million. This growth was driven by a substantial increase in membership to approximately 3.17 million. The medical loss ratio improved to 70.5%, reflecting disciplined pricing and favorable claims development, despite regulatory changes and potential new tariffs posing external factors for future medical costs and membership.
Oscar Health (NYSE: OSCR) Q1 2026 profit jumps as revenue grows
Oscar Health (NYSE: OSCR) reported a significant profit increase in Q1 2026, with total revenue rising to $4.6 billion from $3.0 billion previously, driven by higher membership and rate increases. The company's net income attributable to Oscar reached $679.0 million, and Adjusted EBITDA was $727.1 million, reflecting improved medical loss ratio and SG&A expense ratio. Oscar Health also reaffirmed its full-year 2026 guidance, expecting continued expansion of margins and profitability.
Oscar Health, Inc. ($OSCR) CEO 2025 Pay Revealed
Oscar Health, Inc.'s CEO, Mark T. Bertolini, is estimated to have received $1,149,308 in compensation in 2025, a 20.39% increase from 2024, based on a recent SEC filing. The article also details significant insider trading activity, with more sales than purchases, and provides an overview of institutional investor movements and analyst ratings for OSCR stock.
Oscar Health, Inc. ($OSCR) CEO 2025 Pay Revealed
Oscar Health, Inc.'s CEO, Mark T. Bertolini, is estimated to have received $1,149,308 in compensation in 2025, a 20.39% increase from 2024, based on a recent SEC filing. The article also details significant insider trading activity, with 17 sales and 1 purchase in the last six months, and varying hedge fund activities. Additionally, recent analyst ratings show a mix of buy and sell recommendations, with a median price target of $17.0 for the stock.
Oscar Health, Inc. appoints director Siddhartha Sankaran as independent chair of the board
Oscar Health, Inc. has announced the appointment of Siddhartha Sankaran, a current director, as the independent chair of its board. The article confirms this leadership change and was published on April 21, 2026, at 06:42 am EDT by Reuters.
Oscar Health, Inc. 2026 First Quarter Earnings Conference Call
Oscar Health, Inc. (NYSE: OSCR) is set to release its first quarter 2026 financial results before the market opens on Wednesday, May 6, 2026. The company will host a conference call at 8:00 AM ET to discuss these results, with details provided for live call access and webcast viewing. An archive of the call will be available on Oscar's investor relations website for 90 days.
Oscar Health director granted 1,461 deferred units | OSCR Insider Trading
Oscar Health director David Plouffe was granted 1,461 deferred stock units as board compensation, with each unit representing one share of Class A common stock. The units, fully vested on the grant date of April 9, 2026, were based on a closing stock price of $14.54. Following this transaction, Plouffe directly holds 6,854 deferred stock units, which will be settled in cash or stock under specific future conditions.
Oscar Health (NYSE: OSCR) director takes fees in 3,610 deferred units
Oscar Health director Jeffery H. Boyd received a grant of 3,610 deferred stock units as compensation for his board service, valued at $14.54 per unit based on the closing share price on April 9, 2026. These units are granted in lieu of cash retainer payments under the company’s deferred compensation plan for directors. Following this transaction, Boyd directly holds 69,858 deferred stock units, which will be settled in cash or shares by Oscar Health's discretion after specific events.
Director Gassen takes Oscar Health (OSCR) board fees in stock units
Oscar Health director William Gassen received 1,418 deferred stock units as compensation for his board service. These units, valued at $14.54 per share based on the April 9, 2026 closing price, bring his total holdings to 6,387 deferred units. This transaction represents equity-based compensation in lieu of cash, with settlement contingent on specified service-ending events.
Oscar Health (OSCR) director granted 1,203 deferred stock units in lieu of cash
Oscar Health director Sid Sankaran was granted 1,203 deferred stock units (DSUs) as compensation for board service, in lieu of cash payments. These DSUs, valued at $14.54 per share based on the April 9, 2026 closing price, are 100% vested on the grant date. They will be settled in cash or Class A shares at the company's discretion within 45 days after specific events like termination of service or a change in control.
Oscar Health (OSCR) Is Up 22.0% After CEO’s US$11.9M Share Purchase And Regulatory Tailwind - Has The Bull Case Changed?
Oscar Health's CEO, Mark Bertolini, recently purchased US$11.9 million in company shares, increasing his ownership above 10% and signaling strong confidence. This insider buying, combined with favorable Medicare Advantage reimbursement updates, has boosted the company's stock by 22.0%. The article examines whether these developments alter Oscar Health's investment narrative, particularly concerning its path to sustained profitability and managing medical costs.
1OSCR.MI Stock Price, Quote & Chart | OSCAR HEALTH INC - CLASS A (BIT:1OSCR)
OSCAR HEALTH INC - CLASS A (BIT:1OSCR) stock closed at 12.57 EUR, up 7.44% on April 9, 2026. The company reported missed EPS and revenue expectations in Q4 2025, but analysts forecast significant growth in EPS (132.83%) and revenue (56.29%) for the next year. ChartMill assigned technical and fundamental ratings of 1/10 and 4/10 respectively, citing concerns about profitability despite average financial health.
Bertolini buys Oscar Health (OSCR) shares for $11.92 million By Investing.com
Mark T. Bertolini, CEO of Oscar Health (OSCR), recently purchased 1,000,000 shares for $11.92 million. Despite wider-than-expected losses in Q4 2025 and missed revenue forecasts, analysts predict profitability for 2026, with Raymond James upgrading the stock to Outperform. The company's stock has seen an 11% return, and InvestingPro suggests it is currently undervalued.
Assessing Oscar Health (OSCR) Valuation As Revenue Growth And Efficiency Gains Draw Fresh Investor Attention
Oscar Health (OSCR) has attracted renewed investor interest due to 41.2% annual revenue growth and improved adjusted operating profits driven by efficiency gains. Despite recent share price pullbacks, longer-term shareholders have seen strong returns. The company is considered undervalued by some analysts, with a fair value of $15.40 against a closing price of $12.97, supported by substantial capital reserves and low leverage, though potential risks like higher claims costs in the ACA market exist.
Bertolini buys Oscar Health (OSCR) shares for $11.92 million By Investing.com
Oscar Health CEO Mark T. Bertolini recently purchased 1,000,000 shares of Class A Common Stock for $11.92 million, with the stock rising 11% since then. InvestingPro analysis suggests the company is undervalued with a fair value of $15.87 and analysts predict profitability for 2026. Despite a Q4 2025 earnings miss, Raymond James upgraded Oscar Health's stock to Outperform, setting an $18.00 price target due to attractive valuation and recovering margins.
Bertolini buys Oscar Health (OSCR) shares for $11.92 million By Investing.com
Mark T. Bertolini, CEO of Oscar Health (NASDAQ:OSCR), recently purchased 1,000,000 shares for $11.92 million, while also disposing of a similar number of shares to cover tax obligations. Despite the stock rising 11% since the purchase, the company recently reported wider-than-expected Q4 2025 losses, though Raymond James upgraded its rating to Outperform with an $18 price target, citing attractive valuation as margins recover.
Oscar Health Stock Jumps After CEO Buys $11.92 Million In Shares
Oscar Health (OSCR) stock surged after CEO Mark Bertolini purchased 1 million Class A shares for $11.92 million, signaling strong confidence in the company. The tech-focused health insurer focuses on ACA plans and recently reported record membership of 3.4 million, maintaining a constructive outlook amidst broader positive developments in managed care. The stock's RSI also rebounded towards the upper neutral range, suggesting balanced momentum.
Oscar Health Stock Rises After CMS Finalizes 2027 Medicare Advantage Payment Update
Oscar Health (NYSE: OSCR) shares rose slightly after the CMS finalized its 2027 Medicare Advantage and Part D payment policies, aiming to improve payment accuracy and control cost inflation. The changes are projected to increase Medicare Advantage payments by 2.48% for 2027. While Oscar Health's business is more focused on ACA plans, rather than being a pure Medicare Advantage provider, investors are monitoring broader implications for payment integrity and risk adjustment across managed care.
Bertolini buys Oscar Health (OSCR) shares for $11.92 million By Investing.com
Oscar Health CEO Mark T. Bertolini recently purchased 1,000,000 shares of Class A Common Stock for $11.92 million. While the stock has seen an 11% return, the company recently reported wider-than-expected losses for Q4 2025. Despite financial misses, Raymond James upgraded Oscar Health's stock to Outperform, citing attractive relative valuation and recovering margins.
Oscar Health (OSCR) CEO exercises 5.7M PSUs and buys 1M shares in April transactions
Oscar Health CEO Mark T. Bertolini engaged in significant equity transactions in April 2026, including exercising 5,733,334 performance stock units (PSUs) and purchasing 1,000,000 Class A shares in a private placement at $11.92 per share. Concurrently, 1,000,001 shares were withheld by the company to cover tax obligations related to the vested PSUs. Following these activities, Bertolini directly holds 10,196,876 Class A shares, with future PSU settlements and tax-related sales to be conducted under a Rule 10b5-1 instruction letter.
Bertolini buys Oscar Health (OSCR) shares for $11.92 million By Investing.com
Oscar Health (OSCR) CEO Mark T. Bertolini recently purchased 1,000,000 shares for $11.92 million, with the stock subsequently rising 11%. Despite a recent Q4 2025 earnings miss and wider-than-expected losses, Oscar Health is deemed undervalued by InvestingPro with a Fair Value of $15.87, and analysts predict profitability in 2026. Raymond James upgraded the stock to Outperform with an $18.00 price target, citing attractive valuation as margins recover in the Affordable Care Act exchange market.
Vanguard disaggregates holdings; OSCR parent reports 0 shares (Vanguard)
The Vanguard Group has filed an amended Schedule 13G/A report indicating zero beneficial ownership in Oscar Health Inc. This change follows an internal realignment effective January 12, 2026, where Vanguard disaggregated its reporting structure, meaning certain subsidiaries will now report beneficial ownership separately. The filing confirms that The Vanguard Group, as the parent entity, no longer holds voting or dispositive power over Oscar Health shares following this administrative change.
A Look At Oscar Health (OSCR) Valuation As Earnings Projections And Margins Improve
Oscar Health (OSCR) is showing improving earnings projections and margins, despite recent stock price declines. The company is considered undervalued with a fair value of $15.78, significantly higher than its current trading price of $11.14. This valuation is based on positive earnings, margin shifts, and future revenue growth, although risks like higher claims costs from ACA changes remain.
Oscar Health’s Platform Shift And Expansion Set Against Mixed Share Performance
Oscar Health is transitioning from a tech-enabled insurer to a scalable healthcare platform, showing operational improvements and using its balance sheet for expansion. While longer-term shareholder returns have been strong, recent performance has been weaker. Analysts are targeting a higher price for OSCR, and the company's shift towards an infrastructure-oriented role in healthcare is a key factor for investors to consider.
Is Oscar Health (OSCR) Quietly Becoming an Infrastructure-Like Platform or Still Just an Insurer?
Oscar Health is drawing attention as analysts project significant EPS improvement, revenue growth, and margin gains, framing the company as a scaled, infrastructure-like healthcare platform. Its reaffirmed 2026 guidance for revenue between US$18.7–US$19.0 billion and operational earnings of US$250–US$450 million is central to its profitability narrative. Despite a recent stock pullback, the firm's long-term forecast suggests substantial earnings growth and a fair value of $15.78, indicating a potential 29% upside.
OSCAR HEALTH, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler F
Wolf Haldenstein Adler Freeman & Herz LLP has announced that a securities class action lawsuit has been filed against Oscar Health, Inc. in the United States District Court for the Southern District of New York. The lawsuit was filed in connection with an alert published by PRNewswire on May 26, 2022.
Assessing Oscar Health (OSCR) Valuation After Mixed Returns And A Possible Undervaluation Gap
Oscar Health (OSCR) has experienced mixed share performance recently, with a slight daily decline but strong long-term returns. Despite recent fluctuations, the stock is currently trading below its analyst target and fair value estimate, suggesting a potential undervaluation. However, this valuation relies on optimistic assumptions regarding revenue expansion and margin improvements, which could be impacted by factors like higher claims costs and policy shifts.
How Oscar Health Inc. Class A (OSCR) Affects Rotational Strategy Timing
This article analyzes how Oscar Health Inc. Class A (OSCR) impacts rotational strategy timing, identifying strong near-term sentiment but a neutral mid and long-term outlook with elevated downside risk. It provides institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for OSCR. The analysis is based on AI-generated signals and quantitative research.
Oscar Health (OSCR) CFO Blackley gifts 225,000 shares to family trust
Oscar Health, Inc. CFO Richard Scott Blackley reported bona fide gifts of 225,000 shares of Class A Common Stock on March 12, 2026, to an irrevocable trust for a family member. These transactions were coded as gift transfers with a price of $0.00 per share. Following these gifts, Blackley directly holds 1,316,660 shares and indirectly holds 75,000 shares through the MQB Irrevocable Trust.
Oscar Health, Inc. Class A Common Stock (NY: OSCR
This article compiles recent news headlines related to Oscar Health, Inc. (NYSE: OSCR) Class A Common Stock, covering events from September 2025 to October 2025. News items include stock movements, analyst insights, financial offerings, and discussions around company performance and market trends. Key topics feature a convertible notes offering, changes in stock momentum, and comparisons to other health tech companies.
Do Analyst Upgrades Really Mark a Turning Point in Oscar Health’s (OSCR) Margin Story?
Oscar Health, Inc. (OSCR) has recently garnered attention due to analyst upgrades highlighting expected year-over-year earnings growth, robust revenue expansion, and improved cost controls. This optimism, particularly an upgrade from Raymond James, underscores growing confidence in Oscar Health’s margin outlook despite industry pressures. The article explores how this analyst sentiment could influence Oscar’s investment narrative, emphasizing that while the outlook for profitability is positive, risks from medical costs and regulatory changes remain.
Oscar Health Valuation After Raymond James Upgrade And Margin Expansion Outlook
Oscar Health (OSCR) recently received an Outperform upgrade from Raymond James, moving up from a Market Perform rating, due to potential margin expansion from a stabilizing Affordable Care Act exchange market and improved administrative efficiency. Despite a mixed recent share price performance, the stock trades at an 18% discount to the analyst price target of $15.40, with a fair value estimated at $15.78, indicating it is undervalued. The increased fair value is supported by expectations of strong execution in pricing, margins, and product expansion, particularly in Florida, alongside tighter cost control.
Net debt of Oscar Health, Inc. Class A – DUS:9VY
This article provides financial information for Oscar Health, Inc. Class A (DUS:9VY), specifically focusing on its net debt. The content indicates data is sourced from ICE Data Services, FactSet, and quartr. The main body of the article appears to be a stub or placeholder without specific net debt values, directing the user to select market data.
How Reaffirmed 2026 Outlook and Surging Membership Will Impact Oscar Health (OSCR) Investors
Oscar Health's recent presentation at the Raymond James conference reaffirmed its 2026 outlook and highlighted stronger-than-expected enrollment of 3.4 million members. The company's strategy involves balancing membership-driven revenue growth with capital access and risk sharing, aiming for sustainable profitability by 2026. Despite positive developments like a new credit facility and reinsurance support, investors still need to consider the exposure to potential changes in ACA subsidies and market shifts.
Oscar Health (OSCR) president granted 106,458 RSUs and sells 7,453 shares
Oscar Health's President, Janet Liang, was granted 106,458 restricted stock units (RSUs) that will vest quarterly over three years starting June 1, 2026. Concurrently, she sold 7,453 shares of Class A common stock at a weighted average price of $13.39 to satisfy tax withholding obligations from previously vested equity awards. This combination of a compensatory grant and a tax-driven sale is considered a routine executive transaction, with analysts marking its impact as neutral.
Average basic shares outstanding of Oscar Health, Inc. Class A – FWB:9VY
This article provides the average basic shares outstanding for Oscar Health, Inc. Class A, traded on the Frankfurt Stock Exchange under the ticker FWB:9VY. It is a data-focused piece from TradingView, indicating no specific values but offering a view of the company's financial metrics over different periods.
Oscar Health (OSCR) CEO Mark Bertolini awarded 1.6M restricted stock units
Oscar Health CEO Mark T. Bertolini was granted 1,596,877 restricted stock units (RSUs) of Class A common stock, which will vest in three equal annual installments starting on March 2, 2027. This equity award is granted at $0.00 per share and requires his continued service as CEO or a board member for vesting. Following this grant, Bertolini's total beneficial ownership in Oscar Health (OSCR) stands at 4,463,543 shares, including future vesting RSUs.
A Look At Oscar Health’s Valuation After Reaffirmed 2026 Guidance At Raymond James Conference
Oscar Health (OSCR) recently reaffirmed its full-year 2026 guidance at the 47th Annual Raymond James Institutional Investor Conference, bringing its valuation back into focus. Despite mixed recent stock performance, the company's valuation narrative suggests it is about 8.8% undervalued with a fair value of $15.78 against its current trading price of $14.39. The reaffirmed guidance is underpinned by expectations of revenue growth, rising profitability, and potential margin recovery through aggressive repricing and productive regulatory engagement.
Oscar Health chief accounting officer Baltrus sells $62k in stock By Investing.com
Oscar Health's Chief Accounting Officer, Victoria Baltrus, sold 4,638 shares for approximately $62,102 on March 2, 2026, though she also acquired 17,300 restricted stock units. Despite the recent sale, the company's stock has risen, and analysts anticipate profitability this year. Raymond James upgraded Oscar Health's stock to Outperform, citing attractive valuation and improving margins in the Affordable Care Act exchange market.
Oscar Health (OSCR) CLO awarded 67,424 RSUs and sells 18,710 shares
Oscar Health's Chief Legal Officer, Adam McAnaney, was awarded 67,424 restricted stock units (RSUs) which will vest quarterly in 12 equal installments starting June 1, 2026. On the same date, he sold 18,710 shares of Class A common stock at a weighted average price of $13.39 per share. This sale was conducted under a Rule 10b5-1 plan to cover tax withholding obligations from previous equity awards, and after these transactions, he directly owns 227,955 shares.
Oscar Health, Inc. Class A Trade Ideas — FWB:9VY
This article compiles various trade ideas and technical analyses for Oscar Health, Inc. Class A (FWB:9VY, NYSE:OSCR). Traders present both bullish and bearish outlooks, discussing price consolidation, potential breakouts, Fibonacci levels, earnings expectations, and technical indicators like RSI and MACD. The diverse perspectives highlight different trading strategies and risk assessments for the stock.
Oscar Health chief accounting officer Baltrus sells $62k in stock
Oscar Health, Inc.'s Chief Accounting Officer, Victoria Baltrus, sold 4,638 shares of Class A Common Stock for approximately $62,102 in early March 2026, while also acquiring 17,300 shares through restricted stock units. Despite an earnings miss in Q4 2025, Oscar Health's stock rose, driven by strong forward guidance and an upgrade from Raymond James to Outperform. The company is predicted to turn profitable this year, according to InvestingPro analysis.
OSCR SEC Filings - Oscar Health Inc 10-K, 10-Q, 8-K Forms
This page provides access to Oscar Health Inc.'s SEC filings including 10-K, 10-Q, 8-K, and insider trading forms, with AI-powered tools to interpret the complex documents. It details recent filings like an 8-K on preliminary Q2 2025 results and a Form 144 for a share sale, along with financial data and current stock information for OSCR.
Should Options Spike and ACA Policy Jitters Require Action From Oscar Health (OSCR) Investors?
Oscar Health (OSCR) has recently experienced increased call-option trading and higher implied volatility, driven by ownership changes, missed earnings, and concerns over Affordable Care Act (ACA) policy risks. Institutional investors are re-evaluating Oscar's position in ACA markets due to expiring enhanced subsidies and regulatory uncertainty, which could impact membership and profitability. The article examines how these factors could influence Oscar Health's investment narrative and risk profile, noting that while some analysts project significant future growth and fair value upside, cautious perspectives anticipate flatter revenues and modest profitability.
